The reform debate about hospital consolidation begins with a fact that the prior articles have established: the antitrust framework, applied with the most sustained enforcement ambition in a generation, proved insufficient to the scale of market power the consolidation documented in this hub has produced. That is the starting point for taking reform proposals seriously — not as alternatives to enforcement but as responses to what enforcement alone cannot accomplish.
The proposals that emerge from that starting point fall into four categories. Each addresses a real dimension of the consolidation problem. Each has evidence behind it. Each has limits. And underlying all of them is a structural question the reform debate has not yet fully resolved — a question that the closing article of this hub addresses directly.
Stronger antitrust enforcement and structural remedies
The case for stronger antitrust enforcement begins with the observation that the Khan-era enforcement push, however ambitious, operated within legal constraints that courts have consistently interpreted in ways favorable to merging parties. The market definition problem, the cross-market merger gap, the vertical integration threshold problem — these are not fixed features of antitrust law. They are interpretive choices that different courts, applying different analytical frameworks, have made differently.
The structural remedy proposals that go beyond behavioral consent decrees include mandatory divestiture of acquired facilities where post-merger concentration exceeds defined thresholds, lower Hart-Scott-Rodino filing thresholds that would bring more transactions into mandatory review, and expanded authority for retrospective review of mergers that produce documented competitive harm after approval. Each of these requires either legislative action — to change the statutory framework — or sustained judicial acceptance of more expansive antitrust theories than courts have generally endorsed.
The honest assessment of structural antitrust remedies is that they are necessary and insufficient. Necessary because blocking anticompetitive mergers before they occur is substantially more effective than unwinding them after the fact, and because the behavioral remedies that have substituted for structural ones have a poor track record. Insufficient because, as the following section addresses, some hospital markets have consolidated to the point where restoring competition through divestiture would require unwinding years of acquisitions in communities that have reorganized their clinical infrastructure around the consolidated system — a practical and political undertaking that has not been achieved in any major hospital market.
Price regulation and rate-setting
Where competition cannot be restored — and the evidence suggests that is true of a significant share of American hospital markets — the alternative is regulation of the prices that market power would otherwise allow consolidated systems to extract. Price regulation in healthcare takes several forms, from the blunt instrument of price caps to the more sophisticated approach of reference pricing that ties commercial rates to a regulated benchmark.
The reference pricing proposals most actively discussed in the hospital context would cap commercial hospital rates at a defined multiple of Medicare rates — typically 150 to 200 percent of what Medicare pays for the same service. The logic is straightforward: Medicare rates, set by the government through a defined formula, are not subject to the leverage dynamics that allow consolidated systems to extract above-market rates from commercial insurers. Tying commercial rates to Medicare rates would substantially reduce the price differential between consolidated and competitive markets.
The objections to price regulation are real and should be taken seriously. Hospital systems argue that Medicare rates are systematically below the cost of care — that the cross-subsidy from commercial payers to Medicare and Medicaid patients is what makes serving those patients financially viable. If that argument is correct, reducing commercial rates would threaten the financial viability of hospitals serving high proportions of Medicare and Medicaid patients. If it is not — if the margin between commercial rates and actual cost of care reflects market power extraction rather than legitimate cost recovery — then the objection is an argument for preserving the extraction rather than for the clinical necessity of high commercial rates.
The evidence on the relationship between commercial rate levels and hospital financial viability is contested. What is not contested is that the hospitals extracting the highest commercial rates relative to Medicare are not systematically the hospitals serving the highest proportions of Medicare and Medicaid patients. The hospitals with the greatest market power tend to be large systems in affluent markets — exactly the hospitals least dependent on Medicare and Medicaid cross-subsidy to sustain their operations.
Global budgeting and all-payer models: the Maryland evidence
The most significant American evidence on an alternative to both competition and individual price regulation comes from Maryland, which has operated an all-payer hospital rate-setting system since 1977 and transitioned to a global budget model in 2014.
Under Maryland’s all-payer model, a state commission sets the rates that all payers — Medicare, Medicaid, and commercial insurers — pay for hospital services. Every payer pays the same rate for the same service at the same hospital. The system eliminates the leverage dynamic that drives price differences between payers: there is no commercial rate to negotiate because the rate is set. There is no Medicare rate differential to cross-subsidize because all payers pay the same rate.
The 2014 transition to global budgets extended the model further. Under global budgeting, each hospital receives a fixed annual budget — a total payment for all the care it delivers to its defined population — rather than a per-service payment. The incentive structure shifts: a hospital that reduces unnecessary admissions, manages chronic disease effectively in outpatient settings, and keeps patients out of the hospital retains the budget savings rather than losing revenue. The financial logic of volume-driven care delivery is replaced by the financial logic of population health management.
The outcomes documented under Maryland’s global budget model are meaningful. Hospital cost growth in Maryland has been consistently below the national average since the global budget transition. Medicare spending per beneficiary in Maryland — the metric that determined whether the state met its agreement with the federal Centers for Medicare and Medicaid Services — declined relative to national trends. Preventable hospitalizations fell. The model has not resolved all of Maryland’s healthcare cost challenges, and Maryland’s hospital prices remain above the national average in absolute terms — a legacy of the rate-setting history before the global budget transition. But the directional evidence is consistent: global budgeting produces cost containment and shifts hospital incentives toward population health in ways that neither competition nor individual price regulation has demonstrated at comparable scale.
The Maryland model is not directly replicable in every state — it required a federal waiver, a state-level regulatory infrastructure built over decades, and a political consensus that has not existed in most states. But it is the most developed American evidence base for what rate-setting at scale produces, and the reform debate that ignores it is working with an incomplete picture.
Ownership restrictions
The private equity acquisition dynamic documented in Article 4 has generated a distinct category of reform proposals: restrictions on the forms of ownership that are permitted in the hospital market.
Several states have enacted or proposed legislation requiring regulatory approval for private equity acquisitions of healthcare entities, extending the certificate of need review process to ownership transfers, or prohibiting certain ownership structures in specific healthcare settings. Massachusetts, California, and Oregon have moved furthest in this direction, establishing review processes for healthcare transactions — including PE acquisitions — that assess community impact alongside competitive effects.
Federal legislative proposals have included requirements for PE-owned healthcare entities to disclose their ownership structure and financial arrangements, extended antitrust review thresholds that would capture PE acquisitions currently below mandatory filing requirements, and restrictions on the debt loading practices that characterize PE healthcare acquisitions.
The ownership restriction proposals face a constitutional and legal environment that has not fully resolved how far states and the federal government can go in restricting the forms of permissible ownership in a private market. The policy case for restrictions on PE ownership specifically — as distinct from restrictions on consolidation generally — rests on the documented relationship between PE ownership structure and patient outcomes: the exit horizon, the debt loading, and the operating decisions those structural features produce. The case is strong enough that the reform debate increasingly treats PE healthcare ownership as a distinct problem requiring distinct responses rather than a subcategory of the general consolidation question.
The natural monopoly problem
The reform proposals documented in the preceding sections share an assumption that is worth naming directly: that the hospital market is, in principle, amenable to competitive discipline if the right regulatory conditions are established. That assumption is not universally true.
Some hospital markets are natural monopolies. A rural county with one hospital does not have a hospital market in any competitive sense — it has a hospital. Restoring competition in that market is not a regulatory challenge; it is a geographic and demographic impossibility. The single hospital in a rural county will always have the market power of the only available provider, regardless of what antitrust framework governs it. The question for that community is not how to make the market competitive but how to ensure that the monopoly provider serves the community’s needs at a price the community can sustain.
The natural monopoly problem is not confined to rural markets. Urban and suburban markets that have consolidated to the point where one or two systems control the substantial majority of hospital capacity face a similar structural condition — not geographic monopoly but market monopoly that competition policy cannot restore without structural intervention on a scale that has not been politically or practically achievable in any American market.
For natural monopoly markets, the policy options are regulation — of prices, of service obligations, of ownership — rather than competition restoration. The Maryland model is the most developed American example of a regulatory approach designed for markets where competition is not the answer. The international evidence — from countries where hospital markets operate under administered rates or global budgets rather than competitive pricing — is the broader evidence base. Both point toward the conclusion that regulation of market power, rather than restoration of competition, is the operative policy framework for a significant share of American hospital markets.
The structural question the reform debate has not resolved
The reform proposals documented in this article — stronger antitrust enforcement, price regulation, global budgeting, ownership restrictions — each address real dimensions of the consolidation problem. Applied together, with sufficient political will and regulatory capacity, they would produce a hospital market with meaningfully less consolidated market power, more constrained pricing, and better aligned incentives than the current market.
They do not resolve the structural question that underlies the consolidation dynamic in the first place: why hospital market power exists and why it is so difficult to constrain. The answer the evidence from this hub supports is that hospital market power is a product of a financing structure that rewards market leverage — that the multi-payer insurance market, in which prices are set through bilateral negotiation between systems and insurers, systematically produces higher prices wherever one party to that negotiation has more leverage than the other. Consolidation is the mechanism through which hospitals acquire that leverage. The consolidation is a response to the financing structure.
What a different financing structure would produce — one in which administered rates replaced negotiated rates, in which market leverage was structurally irrelevant because prices were not set through leverage — is the question the closing article examines.
All Hospital Consolidation Articles
00 — Hospital Consolidation Hub
01 — How Hospital Consolidation Works — and What It Produces
02 — Horizontal Merger: When Hospitals Buy Hospitals
03 — Vertical Integration: When Systems Acquire Everything
04 — Private Equity in Healthcare: What Happens When Hospitals Become Assets
05 — How Consolidation Drives Up Prices
06 — What Consolidation Does to Quality and Staffing
07 — How Consolidated Systems Squeeze Independent Physicians
08 — Rural Hospital Closures and the Consolidation Connection
09 — Why Antitrust Enforcement Failed the Hospital Market
10 — What Would Change It: Consolidation, Competition, and the Reform Debate
11 — What Single-Payer Resolves — and What It Doesn’t: The Evidence From This Hub
12 — Join the conversation in the Health Care Forum
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.